Background
An estimated 35.3 million people globally are living with HIV (UNAIDS, 2013). A number of prevention methods are available, from condoms to male circumcision, prevention of mother-to-child transmission to clean needles, but to date these have not been sufficient to stop the epidemic. In 2012 alone, an estimated 2.3 million people became newly infected (UNAIDS, 2013). Additional safe and effective approaches to HIV prevention are urgently needed.
Men who have sex with men (MSM) have a disproportionate burden of HIV in most countries in the world, even in many countries with generalized HIV epidemics. Worldwide, for MSM, the odds of being infected with HIV are 19.3 times higher than for men in the general population (Baral et al., 2007). Although there are a variety of existing efficacious HIV prevention interventions for MSM, they face political and structural barriers to accessing services in many settings due to their stigmatized and marginalized status. The disproportionate burden of HIV faced by MSM suggests that existing methods of HIV prevention are not sufficient and additional prevention modalities would be helpful.
Pre-exposure prophylaxis (PrEP) is the use of an antiretroviral drug to block the acquisition of HIV infection by uninfected people. Proof of concept has long been established in the laboratory by animal studies and in real world application by the prevention of mother-to-child transmission and post-exposure prophylaxis. The safety of the drugs being considered for PrEP, tenofovir and emtricitabine, has been established through their use for treatment and in safety trials in uninfected people (Peterson et al., 2007). Five trials of effectiveness (Phase IIb and Phase III) have been conducted in the last decade. These focus on effectiveness of PrEP among people who inject drugs, serodiscordant couples, heterosexual women and high risk MSM.
The first trial to produce results was the iPrEx trial (Grant et al., 2010). This Phase III clinical trial tested whether a daily combination of tenofovir and emtricitabine could safely and effectively prevent HIV infection among MSM. Of the five effectiveness trials, this trial conducted in six countries on four continents was the only one to examine efficacy in MSM.
The iPrEx study demonstrated a 44% reduction in HIV transmission on the modified intention-to-treat analysis. Adherence to the recommended regimen was lower than expected, though it varied by country. For those men who reported taking the pills on 90% or more days, however, the efficacy of PrEP was 73%. Resistance was only found in two participants who had an existing acute HIV infection undetected at baseline and who were randomized to active drug. Few concerns about safety were detected. A marked trend toward risk reduction, specifically increased condom use and decreased number of partners, was reported in both arms and all sites.
In 2012, WHO developed guidelines for PrEP for serodiscordant couples, MSM, and transgender people (TG) at high risk of HIV (WHO, 2012). This systematic review updates the review of PrEP for MSM that was completed for those guidelines. This systematic review examined the following PICO question: Should oral PrEP (containing tenofovir (TDF)) be used for HIV prevention among men who have sex with men? A few minor changes were made to the PICO question from the earlier guidelines. First, the new PICO question includes only MSM, not transgender people. Second, the new PICO question covers all oral PrEP containing tenofovir, as opposed to the previous PICO question which focused specifically on the combination of emtricitabine (FTC 200mg) and tenofovir (TDF 300 mg) used in the iPrEx study.
In addition, in 2011, a review of values and preferences of MSM about PrEP was conducted through a review of published literature. However, most of the studies available at that time were based on data collected before the iPrEx trial results were available. Values and preferences may have changed now that MSM are aware of the partial effectiveness of PrEP. This values and preferences literature review was also updated to capture literature through the end of 2013, with a focus on studies that collected data after iPrEx study results were released.
Methods
PICO question
PICO 1: Should oral PrEP (containing tenofovir (TDF)) be used for HIV prevention among men who have sex with men?
P: Men who have sex with men
I: Oral PrEP (containing tenofovir (TDF))
C: Placebo
O: (1) HIV infection, (2) any adverse event, (3) any stage 3 or 4 adverse event, (4) condom use, and (5) number of sexual partners
Inclusion criteria
To be included in the review, an article had to meet the following criteria:
Randomized controlled trial evaluating the use of oral PrEP (containing tenofovir (TDF)) to prevent HIV infection among MSM participants.
Measured one or more of the following key outcomes: (1) HIV infection, (2) any adverse event, (3) any stage 3 or 4 adverse event, (4) condom use, and (5) number of sexual partners.
Published in a peer-reviewed journal, or presented as an abstract at a scientific conference, between January 1, 1990 and January 1, 2014.
No restrictions were placed based on location of the intervention. No language restrictions were used on the search. Articles in languages other than English were translated where necessary.
Following the GRADE approach, if direct evidence from MSM populations was limited for one or more of the key outcomes, indirect evidence from other populations (e.g., heterosexual men) would have been instead, but downgraded for indirectness. If evidence from other populations was limited, evidence from non-randomized but controlled studies would have been used instead, but also downgraded for directness.
Search strategy
The following electronic databases were searched using the date ranges January 1, 1990 to January 1, 2014: PubMed, CINAHL (Cumulative Index to Nursing and Allied Health Literature), and EMBASE. Secondary reference searching was conducted on all studies included in the review. Further, selected experts in the field were contacted to identify additional articles not identified through other search methods.
Abstracts from the following conferences were searched from January 1, 1990 to January 1, 2014: International AIDS Conference (IAC) and IAS Conference on HIV Pathogenesis, Treatment, and Prevention (IAS). We had planned to search the Conference on Retroviruses and Opportunistic Infections (CROI) as well, but abstracts from this conference were no longer available online to the public at the time the search was conducted.
Search terms
The following terms were entered into all computer databases:
(“men who have sex with men” or MSM or transgender or TG or “gay men”) AND (“pre-exposure prophylaxis” or PrEP or emtricitabine or tenofovir or Truvada or FTC or TDF) AND (HIV OR AIDS)
The search for abstracts was more difficult given the search engines available on conference websites. For each conference, a search was first conducted for all abstracts including the word “PrEP”. These search results were then further searched for keywords regarding MSM.
Screening abstracts
Titles, abstracts, citation information, and descriptor terms of citations identified through the search strategy were screened by two reviewers. Full text articles were obtained for all selected abstracts and both reviewers independently assessed all full-text articles for eligibility to determine final study selection. Differences were resolved through consensus.
Articles not meeting the inclusion criteria for the review, but presenting potentially interesting background information relevant to PrEP among MSM, including review articles, qualitative studies, cost or cost-effectiveness analyses, or descriptions of interventions without an evaluation component, were included in an annotated bibliography of additional articles.
Data extraction and management
Data were extracted independently by two reviewers using standardized data extraction forms. Differences in data extraction were resolved through consensus and referral to a senior team member from WHO when necessary. Study authors were contacted when additional information or data were needed.
The following information was gathered from each included study:
Study identification: Author(s); type of citation; year of publication
Study description: Study objectives; location; population characteristics; description of the intervention; study design; sample size; follow-up periods and loss to follow-up
Outcomes: Analytic approach; outcome measures; comparison groups; effect sizes; confidence intervals; significance levels; conclusions; limitations
Risk of bias was assessed using the Cochrane Collaboration's tool for assessing risk of bias (Cochrane Handbook, chapter 8.5 – Higgins & Green, 2011). This tool assesses random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias) incomplete outcome data (attrition bias), and selective reporting (reporting bias). Methodological components of the studies were assessed and classified as high, low, or uncertain risk of bias.
Data analysis
Data were analyzed according to coding categories and outcomes. If multiple studies reported the same outcome, meta-analysis would have been conducted using random-effects models to combine effect sizes with the program Comprehensive Meta-Analysis (CMA). Data were summarized in GRADE tables, summary of finding tables, and risk/benefit tables.
Results
Combining search results from both the 2011 and 2014 searches, initial database searching yielded 764 citations and 139 conference abstracts; one additional study was identified through other means, such as searching through the reference lists of relevant articles (). Once all duplicates were removed, 609 records were reviewed and 348 article citations and 119 abstracts were excluded for being unrelated to the study topic. After thoroughly reviewing the remaining 142 articles and abstracts, 3 were excluded for being unrelated to the study topic, 4 did not meet the study design criteria, and 128 were coded as background or values and preferences; an additional 3 conference abstracts presented preliminary data and were used in the 2011 review, although all 3 were later published as peer-reviewed articles and thus were duplicative of other included articles. Ultimately, 4 studies reported in 5 articles were deemed eligible for inclusion in our review. Of these, one was a Phase III efficacy trial, while three were smaller pilot feasibility/acceptability or extended safety studies. Given the discrepancies in the study purposes, drug regimens/dosing schedule, and size/statistical power (and thus imprecision and quality according to the GRADE framework), we generally present results from the primary Phase III efficacy trial below and in GRADE tables, and present additional findings from the smaller studies in the results below along with the efficacy trial. However, for the HIV infection outcome, we were able to merge the results from two studies with the same drug regimen.
Disposition of citations during the search and screening process.
The primary Phase III efficacy trial meeting all inclusion criteria was the iPrEx trial (Grant et al., 2010). This study was a randomized controlled trial to evaluate the safety and efficacy of once-daily oral FTC-TDF as compared with placebo for the prevention of HIV acquisition among MSM. The trial was conducted among 2499 participants in 6 countries: Peru, Ecuador, South Africa, Brazil, Thailand, and the United States. All study participants were born male, although 29 (1%) reported their current gender identity as female. Participants' ages ranged from 18 to 67 years. Using the Cochrane Risk of Bias tool, the study was judged to have low risk of bias across all of the following categories: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective reporting (reporting bias). The study measured all five key outcomes for this review: 1) HIV infection, 2) Any adverse event, 3) Any stage 3 or 4 adverse event, 4) Condom use, and 5) Number of sexual partners.
The smaller safety study was the US CDC Safety Study, a phase II, randomized, double-blind, placebo-controlled, extended safety trial of TDF in MSM in the United States (Grohskopf et al., 2013; Liu et al., 2013). The trial was conducted among 400 MSM aged 18-60 in 3 US cities: Atlanta, Boston, and San Francisco. Participants were randomized in equal numbers to one of 4 study arms: (1) daily TDF beginning at enrollment, (2) daily placebo beginning at enrollment, (3) daily TDF beginning 9 months after enrollment, and (4) daily placebo beginning 9 months after enrollment.
The smaller pilot feasibility and acceptability study was Project PrEPare, a study to examine the feasibility of a combination prevention intervention, including PrEP, for young MSM in the United States (Hosek et al., 2013). The study was conducted among 58 young MSM aged 18-22 in Chicago. Participants were randomized to one of 3 study arms: (1) a behavioral HIV prevention intervention called Many Men, Many Voices (3 MV) alone, (2) 3 MV combined with PrEP (FTC-TDF), and (3) 3 MV combined with placebo.
Finally, one small study examined safety and adherence to intermittent or daily oral FTC-TDF among Kenyan MSM and female sex workers (Mutua et al., 2012). This study randomized 67 MSM and 5 female sex workers to daily FTC-TDF or placebo, or intermittent FTC-TDF or placebo in a 2:1:2:1 ratio.
HIV infection
In the iPrEx study, incident HIV infection was significantly reduced among participants in the FTC-TDF study arm as compared to the control arm using both an intention-to-treat analysis and a modified intention-to-treat excluding participants who had HIV RNA detected at baseline (Grant et al., 2010). In the intention-to-treat analysis, there were 38 incident cases of HIV infection out of 1251 participants in the FTC-TDF study arm and 72 incident HIV infections out of 1248 participants in the control group, resulting in a hazard ratio of 0.53 (95% CI 0.36-0.78, p=0.001). In the modified intention-to-treat analysis, there were 36 incident cases of HIV in the FTC-TDF group (N=1251) and 64 incident cases of HIV in the control group (N=1248). For this analysis, the hazard ratio of HIV infection comparing those in the FTC-TDF group to the control was 0.56 (95% CI 0.37-0.85, p=0.005), thus showing a 44% reduction in the relative risk of HIV infection.
The CDC safety study had 7 seroconversions among 400 participants (Grohskopf et al., 2013). None occurred among participants taking TDF (n=201), 3 occurred among participants taking placebo (n=99), and 3 occurred among delayed arm participants who had not yet started drug (n=100). One occurred in a participant assigned to placebo who was HIV-1 antibody negative at screening and enrollment and then was seropositive at the 1-month visit.
Project PrEPare had zero seroconversions among 58 study participants (Hosek et al., 2013). The Kenya intermittent PrEP study had one incident infection in the placebo arm (Mutua et al., 2012).
Any adverse event
In the iPrEx study, there was no statistically significant difference in reported adverse events between the two study arms (Grant et al., 2010). In the FTC-TDF arm, 867 out of 1251 patients (69%) reported having any adverse event compared to 877 out of 1248 patients (70%) in the control group. The relative risk of having any adverse event comparing the intervention to control group was 0.99 (95% CI 0.94-1.04), which was not statistically significant.
The CDC safety study also found that there was no statistically significant difference in reported adverse events between the two study arms; overall, 2428 adverse events occurred among 334 (90%) participants, with most of mild or moderate severity (Grohskopf et al., 2013).
Project PrEPare reported 6 adverse events total, 5 of which were possibly or probably related to the study drug, all in the FTC-TDF arm.
The study on intermittent PrEP in Kenya found that both dose regimens had similar rates of adverse events (Mutua et al., 2012).
Any stage 3 or 4 adverse event
In the iPrEx study, both study arms also reported similar rates of grade 3 and 4 adverse events (Grant et al., 2010). In the FTC-TDF study arm, 151 out of 1251 patients (12%) reported having a grade 3 or 4 adverse event compared to 164 out of 1248 patients (13%) in the control arm. The relative risk of having any grade 3 of 4 adverse event was 0.92 (95% CI 0.75-1.13) comparing the intervention to control arm, thus showing no statistical difference between the two groups.
The CDC safety study also found that there was no statistically significant difference in grade 3 and 4 adverse events between the two study arms (TDF: 36 events, 13.2 per 100 person-years (py); Placebo: 26 events, 9.9 per 100 py, rate ratio: 1.13 (95% CI: 0.61, 2.11, p=0.703) (Grohskopf et al., 2013). This finding remained consistent in multivariable analyses dichotomized by adherence levels.
Project PrEPare reported three grade 3 adverse events which were possibly or probably related to the study drug, all in the FTC-TDF arm (Hosek et al., 2013).
The study on intermittent PrEP in Kenya found no study-related serious adverse events (Mutua et al., 2012).
Condom use
The iPrEx study found that both groups reported increased condom use (defined as the percent of partners using condoms during receptive intercourse) over the course of the intervention, but that differences in condom use rates between the FTC-TDF arm (N=1251 at baseline) and control arm (N=1248) did not differ significantly (p=0.36) (Grant et al., 2010). To examine this relationship, a linear mixed regression model was fitted with a random intercept and fixed effects for treatment visit and treatment by visit interaction. The p-value is from a Wald test of the treatment by visit interaction which corresponds to whether or not there is a difference during the study period between the FTC-TDF and control groups. The description of the analysis conducted was received as correspondence from the study authors and was not included in the original publication.
The CDC safety study found that overall, the proportion of MSM reporting unprotected anal sex (UAS) in the past 3 months decreased significantly, from 57% at baseline to 48% during months 3-9 and 52% during months 12-24 (p<0.001) (Liu et al., 2013). The change in proportion of men reporting UAS from baseline to months 3-9 was similar between the immediate vs. delayed arms (p=0.15). The proportion of men reporting UAS did not change significantly after initiation of study drug in the delayed arm (p=0.41) or with continuation of drug in the immediate arm (incident rate ratio (IRR)=1.17, 95% CI: 0.98 to 1.39, p=0.09).
Project PrEPare found no statistically significant differences in the distribution of male-to-male UAS acts among the 3 treatment groups across study visits (Hosek et al., 2013). Percentages of participants reporting UAS in the past month at baseline and week 24 were 42% and 42% for the PrEP arm, 40% and 10% for the placebo arm, and 31% and 23% for the no pill arm. There was a non-significant trend of decreasing UAS across all treatment arms from baseline to week 24.
Number of sexual partners
In the iPrEx study, in both study arms, the number of receptive sexual intercourse partners declined from baseline to follow-up over the course of the study; however, there was no significant difference between the number of partners reported in each study group at each time point (p=0.97) (Grant et al., 2010). Results were calculated by fitting a linear mixed regression model with a random intercept and fixed effects for treatment visit and treatment by visit interaction. The p-value is from a Wald test of the treatment by visit interaction which corresponds to whether or not there is a difference during the study period between the arms in the number of sexual partners (total male partners at over a 12 week recall period with whom the participant had oral or anal sex). These results and a description of the analysis conducted were received as correspondence from the study authors and were not included in the original publication.
The CDC safety study found that overall, mean number of sex partners in the past 3 months decreased significantly from 7.25 at baseline to 6.02 during months 3-9 and 5.71 during months 12-24 (p<0.001) (Liu et al., 2013). These declines were similar between the immediate and delayed study arms during months 3-9 (p=0.67), and the mean number of partners did not differ in months 12-24 vs. months 3-9 with initiation of study drug in the delayed arm (IRR=0.93, p=0.22) or continuation of drug in the immediate arm (IRR=0.96, p=0.56).
The Kenya intermittent PrEP study reported slight changes in number of sexual partners over time but did not assess statistical significance.